@article{1d47443d794c4baf8552fa3288f64581,
title = "Antisense antibacterial compounds",
abstract = "Extensive antibiotic use combined with poor historical drug stewardship practices have created a medical crisis in which once treatable bacterial infections are now increasingly unmanageable. To combat this, new antibiotics will need to be developed and safeguarded. An emerging class of antibiotics based upon nuclease-stable antisense technologies has proven valuable in preclinical testing against a variety of bacterial pathogens. This review describes the current state of development of antisense-based antibiotics, the mechanisms thus far employed by these compounds, and possible future avenues of research.",
keywords = "Antibiotic resistance, Antibiotics, Antisense, PPMOs, Peptide-conjugated phosphorodiamidate morpholino oligomers",
author = "Reed Pifer and Greenberg, {David E.}",
note = "Funding Information: This review was funded by grants from the Cystic Fibrosis Foundation (Award GREENB19P0 ) and the US National Institute of Health R01 ( AI141101 ) and T32 training grant ( AI007520 ). D.E.G. is listed as inventor of multiple patents concerning PMO-based antibacterial compounds (US9790495, US10391098, WO2016108930A2, WO2017112885A1, WO2017112888A1). D.E.G has previously received research support from and served as consultant to Sarepta Therapeutics. All authors have disclosed any conflicts of interest and have read the journal's policy on conflicts of interest. All authors have read the authorship agreement. Funding Information: This review was funded by grants from the Cystic Fibrosis Foundation (Award GREENB19P0) and the US National Institute of Health R01 (AI141101) and T32 training grant (AI007520). D.E.G. is listed as inventor of multiple patents concerning PMO-based antibacterial compounds (US9790495, US10391098, WO2016108930A2, WO2017112885A1, WO2017112888A1). D.E.G has previously received research support from and served as consultant to Sarepta Therapeutics. All authors have disclosed any conflicts of interest and have read the journal's policy on conflicts of interest. All authors have read the authorship agreement. Publisher Copyright: {\textcopyright} 2020",
year = "2020",
month = sep,
doi = "10.1016/j.trsl.2020.06.001",
language = "English (US)",
volume = "223",
pages = "89--106",
journal = "Translational Research",
issn = "1931-5244",
publisher = "Mosby Inc.",
}